A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 1, 2005, Pages 199-206

  Kinney, Gene G ^a   O'Brien, Julie A ^a   Lemaire, Wei ^a   Burno, Maryann ^a   Bickel, Denise J ^a   Clements, Michelle K ^a   Chen, Tsing Bau ^a   Wisnoski, David D ^a   Lindsley, Craig W ^a   Tiller, Philip R ^a   Smith, Sheri ^a   Jacobson, Marlene A ^a   Sur, Cyrille ^a   Duggan, Mark E ^a   Pettibone, Douglas J ^a   Conn, P Jeffrey ^b   Williams Jr , David L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 CYANO N (1,3 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; 3,5 DIHYDROXYPHENYLGLYCINE; AMPHETAMINE; CALCIUM ION; GLUTAMIC ACID; METABOTROPIC RECEPTOR 5; QUISQUALIC ACID; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TYPE; CHO CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FLUOROMETRY; HUMAN; HUMAN CELL; LOCOMOTION; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT;

AMINO ACIDS; AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZAMIDES; CELL LINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHO CELLS; CRICETINAE; DOGS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HAPLORHINI; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MICROSOMES, LIVER; MODELS, STATISTICAL; MOTOR ACTIVITY; P-GLYCOPROTEIN; PHTHALIMIDES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; STARTLE REACTION; XANTHENES;

EID: 20144381462     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.079244     Document Type: Article

References (26)

1. Alagarsamy S, Marino MJ, Rouse ST, Gereau IVRW, Heinemann SF, and Conn PJ (1999) Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat Neurosci 2:234-240.
2. Awad H, Hubert GW, Smith Y, Levey AI, and Conn PJ (2000) Metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20:7871-7879.
3. Bhave G, Karim F, Carlton SM, and Gereau RW (2001) Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat Neurosci 4:417-423.
4. Brody SA, Dulawa SC, Conquet F, and Geyer MA (2004) Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry 9:35-41.
5. Chavez-Noriega LE, Schaffhauser HJ-L, and Campbell UC (2002) Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. Curr Drug Targets CNS Neurol Disord 1:261-281.
6. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, Corsi M, Orzi F, and Conquet F (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 4:873-874.
7. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Disc 1:198-210.
8. Conn PJ and Pin J-P (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
9. 3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett 13:351-354.
10. Geyer MA, Krebs-Thomson K, Braff DL, and Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 158:117-154.
11. Hall DA (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 58:1412-1423. Erratum: Mol Pharmacol (2001) 59:161.
12. Hall DA (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 58:1412-1423. Erratum: Mol Pharmacol (2001) 59:161.
13. Hochberg Y (1988) A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802.
14. Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, Bristow LJ, and Conn PJ (2003) Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 306:116-123.
15. Lindsley CW, Wisnoski DD, Duggan ME, Leister WH, Hartman GD, Huff JR, Williams DL Jr, O'Brien JA, Lemaire W, Sur C, et al. (2004) Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 (mGluR5) that potentiate receptor function in vivo. J Med Chem 47:5825-5828.
16. Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, et al. (2003) (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action and neuroprotection. Neuropharmacology 45:895-906.
17. Mannaioni G, Marino MJ, Valenti O, Traynelis SF, and Conn PJ (2001) Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J Neurosci 21:5925-5934.
18. Marino MJ, Williams DL Jr, O'Brien JA, Valenti O, McDonald TP, Clements MK, Wang R, DiLella AG, Hess JF, Kinney GG, et al. (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci USA 100:13668-13673.
19. Moghaddam B (2004) Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology 174:39-44.
20. O'Brien JA, Lemaire W, Chen T-B, Chang RSL, Jacobson MA, Ha SN, Lindsley CW, Schaffhauser HJ, Sur C, Pettibone DJ, et al. (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). Mol Pharmacol 64:731-740.
21. O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN, Wisnoski DD, Lindsley CW, Schaffhauser HJ, Rowe B, Sur C, et al. (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 (mGluR5) in rat forebrain. J Pharmacol Exp Ther 309:568-577.
22. Olney JW, Newcomer JW, and Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533.
23. Salt TE and Binns KE (2000) Contributions of mGlu1 and mGlu5 receptors to interactions with N-methyl-D-aspartate receptor-mediated responses and nociceptive sensory responses of rat thalamic neurons. Neuroscience 100:375-380.
24. Spooren WPJM, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, Porsolt RD, and Gentsch C (2000) Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 295:1267-1275.
25. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R, and Pile A (2001) Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 132:1423-1430.
26. Yamazaki M, Neway WE, Ohe T, Chen I-W, Rowe JF, Hochman JH, Chiba M, and Lin JH (2001) In vitro substrate identification studies for P-glycoprotein- mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 296:723-735.